Top of this page
Skip navigation, go straight to the content
UCB’s new development pipeline
The merger of UCB and Schwarz Pharma has created a rich pipeline of twelve large and small molecules in clinical development for the treatment of sixteen separate conditions.
Small molecule drug / NCE
Antibody-based drug /
| CNS | Indications | Phase 1 | Phase 2 | Phase 3 | Filed | |
|---|---|---|---|---|---|---|
| Vimpat® | epilepsy adjunctive therapy (EU) |  |
||||
| Vimpat® | diabetic neuropathic pain (EU) | |
||||
| Vimpat® | diabetic neuropathic pain (US) | |
||||
| Vimpat® | epilepsy adjunctive therapy (US) | |
||||
| Neupro® | restless legs syndrome (EU) | |
||||
| Neupro® | restless legs syndrome (US) | |
||||
| Neupro® | advanced Parkinson’s disease (US) | |
||||
| Keppra® XR | epilepsy (US) | |
||||
| Keppra® XR | Epilepsy Monotherapy (US) |  |
||||
| Vimpat® | epilepsy monotherapy (US) | |
||||
| Rikelta™ | epilepsy | |
||||
| Rikelta™ | Unverricht Lundborg Disease (ULD) | |
||||
| Xyrem® | fibromyalgia | |
||||
| lacosamide | fibromyalgia |  |
||||
| lacosamide | migraine prophylaxis | |
||||
| rotigotine | fibromyalgia | |
||||
| rotigotine nasal spray | restless legs syndrome | |
||||
| CDP323 | multiple sclerosis | |
||||
| Inflammation | Indications | Phase 1 | Phase 2 | Phase 3 | Filed | |
|---|---|---|---|---|---|---|
| Cimzia® | Crohn’s disease (EU+US) |  |
||||
| Cimzia® | rheumatoid arthritis (US) | |
||||
| Cimzia® | rheumatoid arthritis (EU) |  |
||||
| Cimzia® | psoriasis |  |
||||
| epratuzumab | systemic lupus erythematosus | |
||||
| anti-Sclerostin | bone loss disorders |  |
||||
| Oncology | Indications | Phase 1 | Phase 2 | Phase 3 | Filed | |
|---|---|---|---|---|---|---|
| CDP791 | non-small-cell lung cancer | |
||||
| CMC544 | non-Hodgkin’s lymphoma | |
||||
| Other | Indications | Phase 1 | Phase 2 | Phase 3 | Filed | |
|---|---|---|---|---|---|---|
| fesoterodine | overactive bladder | |
||||
